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Introduction 
Corticosteroids are now accepted the world over as 
an integral part of asthma therapy, but clinicians are 
continually seeking ways of optimizing their use.*In 
particular, the issue of unwanted systemic effects 
is keenly debated. Many questions have been raised 
as to whether it is possible to avoid such effects 
altogether, while still retaining the full therapeutic 
benefit. Indeed some newer corticosteroid agents 
have been designed with this in mind. 
Pharmacokinetic/pharmacodynamic modelling is 
helping to shed light on this complex relationship and 
offers the possibility of predicting side-effects from 
stated doses of individual drugs. Conversely, it may 
be possible to identify dosing levels which would not 
cause clinically unacceptable levels of side-effects. 
This roundtable meeting concentrated on one par- 
ticular inhaled corticosteroid, fluticasone propionate 
(FP), a corticosteroid agent that has been available 
for use in asthma since 1993. This timely review 
provides an update of the extensive in vitrolin vivo 
data available on FP, including comparisons of 
the potency of its anti-inflammatory effects. It also 
summarizes much of the efficacy and safety data that 
have been collected over the years from its clinical 
trial programmes. 
The review examines the extensive array of 
pharmacokinetic information available, both by the 
intravenous and inhaled routes. The kinetics of FP 
have been studied in more than 300 volunteers and 
the data obtained gives an important insight into the 
relationship between circulating corticosteroids and 
systemic effects. This valuable information should 
help all those who advocate corticosteroid treatment 
in asthma, to give them a better appreciation of the 
tolerability issues involved. If the management of 
asthma is to continue to advance, it is important that 
the messages provided by our scientific colleagues are 
not ignored but translated swiftly into good clinical 
practice. 
DONALD DAVIES 
Department of Clinical Pharmacology 
Royal Postgraduate Medical School 
London, U.K. 
0954-6111/95/0A0001+01 $12.0010 0 1995 W. B. Saunders Company Ltd 
